Fiche société
Allist Pharmaceuticals, Inc.
Traitements, essais et publications liés.
Traitements10programmes
Essais3liés
Publications11liées
SourceDBlocale
Traitements
10| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Carboplatin InjectionThis study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy. | Cancer | Phase 3 | À vérifier | China | À vérifier |
| Cisplatin for injectionThis study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy. | Cancer | Phase 3 | À vérifier | China | À vérifier |
| Firmonertinib Mesilate TabletsThis study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy. | Cancer | Phase 3 | À vérifier | China | À vérifier |
| Furmonertinib 160mgThis is a phase Ⅰb multi-center clinical study. To explore the preliminary efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation. The study plans to enroll 30 subjects, including 20 treated patients and 10 treatment-naïve patients. The subjects with disease progression after previous systematic anti-tumor therapy will be randomized to receive Furmonertinib Mesilate 160 mg/day (N=10) or 240 mg/day (N=10), respectively. The treatment-naïve patients do not need to be randomized and all will receive Furmonertinib Mesilate 240 mg/day (N=10) until disease progression, death or intolerability. The primary endpoint is ORR; the secondary study endpoints include DCR, DOR, DepOR, PFS, OS, CNS ORR, safety and the PK profile of Furmonertinib Mesilate and its metabolites (AST5902). In addition, the peripheral blood ctDNA will be collected and analyzed in this study | Cancer | Phase 1 | Ralentissement de la progression | China | À vérifier |
| Furmonertinib 240mgThis is a phase Ⅰb multi-center clinical study. To explore the preliminary efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation. The study plans to enroll 30 subjects, including 20 treated patients and 10 treatment-naïve patients. The subjects with disease progression after previous systematic anti-tumor therapy will be randomized to receive Furmonertinib Mesilate 160 mg/day (N=10) or 240 mg/day (N=10), respectively. The treatment-naïve patients do not need to be randomized and all will receive Furmonertinib Mesilate 240 mg/day (N=10) until disease progression, death or intolerability. The primary endpoint is ORR; the secondary study endpoints include DCR, DOR, DepOR, PFS, OS, CNS ORR, safety and the PK profile of Furmonertinib Mesilate and its metabolites (AST5902). In addition, the peripheral blood ctDNA will be collected and analyzed in this study | Cancer | Phase 1 | Ralentissement de la progression | China | À vérifier |
| JAB 21822Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation. | Cancer | Phase 1 | À vérifier | China | À vérifier |
| Pemetrexed Disodium for InjectionThis study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy. | Cancer | Phase 3 | À vérifier | China | À vérifier |
| Firmonertinib Mesilate TabletsThis study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy. | Cancer | Phase 3 | À vérifier | China | À vérifier |
| JAB 21822Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation. | Cancer | Phase 1 | À vérifier | China | À vérifier |
| Furmonertinib 160mgThis is a phase Ⅰb multi-center clinical study. To explore the preliminary efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation. The study plans to enroll 30 subjects, including 20 treated patients and 10 treatment-naïve patients. The subjects with disease progression after previous systematic anti-tumor therapy will be randomized to receive Furmonertinib Mesilate 160 mg/day (N=10) or 240 mg/day (N=10), respectively. The treatment-naïve patients do not need to be randomized and all will receive Furmonertinib Mesilate 240 mg/day (N=10) until disease progression, death or intolerability. The primary endpoint is ORR; the secondary study endpoints include DCR, DOR, DepOR, PFS, OS, CNS ORR, safety and the PK profile of Furmonertinib Mesilate and its metabolites (AST5902). In addition, the peripheral blood ctDNA will be collected and analyzed in this study | Cancer | Phase 1 | Ralentissement de la progression | China | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Furmonertinib 160mg | Cancer | Phase 1 | NCT04858958 | FAVOUR — Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | COMPLETED |
| JAB 21822 | Cancer | Phase 1 | NCT05276726 | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | RECRUITING |
| Firmonertinib Mesilate Tablets | Cancer | Phase 3 | NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation | RECRUITING |
Publications
11| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Furmonertinib 160mg | A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer. | Frontiers in oncology | ||
| Furmonertinib 160mg | EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review. | Frontiers in oncology | ||
| JAB 21822 | The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRAS mutation. | Human cell | ||
| Carboplatin Injection | Effect of carboplatin injection on Bcl-2 protein expression and apoptosis induction in Raji cells. | European journal of histochemistry : EJH | ||
| Carboplatin Injection | Protective effect of chrysin, a flavonoid, on the genotoxic activity of carboplatin in mice. | Drug and chemical toxicology | ||
| Carboplatin Injection | Ameliorative Effects of Alpha-tocopherol in Carboplatin Induced Toxicity on Histomorphology of Renal Cortex in Rats. | Journal of the College of Physicians and Surgeons--Pakistan : JCPSP | ||
| Cisplatin for injection | Yupingfeng San extract ameliorates cisplatin induced renal interstitial fibrosis via IL-6/JAK/STAT3 mediated restoration of mitochondrial homeostasis. | Journal of ethnopharmacology | ||
| Cisplatin for injection | Phytochemical characterization, molecular docking, and protective efficacy of Cleome droserifolia against cisplatin-induced testicular toxicity. | Journal of ethnopharmacology | ||
| Cisplatin for injection | Salvianolic acid C alleviates acute kidney injury by restoring fructose-1,6-bisphosphatase 1-mediated gluconeogenesis. | Renal failure | ||
| Pemetrexed Disodium for Injection | PPP2R2C promotes aerobic glycolysis and mediates pemetrexed resistance in lung adenocarcinomas by upregulating TCP1-dependent protein folding of glycolytic enzymes. | Respiratory research | ||
| Pemetrexed Disodium for Injection | Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia |